In July 2020, FDA approved the immunotherapy drug Atezolizumab for combined use with the MEK inhibitor Cobimetinib and RAF inhibitor Vemurafenib in BRAF-mutant melanomas (65). This evidence concerns the gene MAP2K7 and melanoma.